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Abstract
Background: Klotho has an important role in insulin signalling and the development of ageing-like
phenotypes in mice. The common functional "KL-VS" variant in the KLOTHO (KL) gene is associated
with longevity in humans but its role in type 2 diabetes is not known. We performed a large case-
control and family-based study to test the hypothesis that KL-VS is associated with type 2 diabetes
in a UK Caucasian population.
Methods: We genotyped 1793 cases, 1619 controls and 1616 subjects from 509 families for the
single nucleotide polymorphism (SNP) F352V (rs9536314) that defines the KL-VS variant. Allele and
genotype frequencies were compared between cases and controls. Family-based analysis was used
to test for over- or under-transmission of V352 to affected offspring.
Results: Despite good power to detect odds ratios of 1.2, there were no significant associations
between alleles or genotypes and type 2 diabetes (V352 allele: odds ratio = 0.96 (0.84–1.09)).
Additional analysis of quantitative trait data in 1177 healthy control subjects showed no association
of the variant with fasting insulin, glucose, triglycerides, HDL- or LDL-cholesterol (all P > 0.05).
However, the HDL-cholesterol levels observed across the genotype groups showed a similar, but
non-significant, pattern to previously reported data.
Conclusion: This is the first large-scale study to examine the association between common
functional variation in KL and type 2 diabetes risk. We have found no evidence that the functional
KL-VS variant is a risk factor for type 2 diabetes in a large UK Caucasian case-control and family-
based study.
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Klotho is a mammalian hormone with an important role
in insulin signalling and the development of ageing-like
phenotypes. Klotho binds to a cell surface receptor and
represses intracellular signals of insulin and insulin-like
growth factor-I (IGF-I) [1]. Mice with a defect in Klotho
expression exhibit phenotypes that are associated with
ageing in humans, including short life span, arteriosclero-
sis and osteoporosis [2]. These mice have reduced blood
glucose and insulin levels, as well as increased insulin sen-
sitivity [2,3]. Conversely, over-expression of Klotho in
mice extends life span and results in insulin resistance [1].
A common variant of the human KLOTHO gene (KL), is
reproducibly associated with longevity [4,5]. The Klotho
protein is encoded by a 50-kb gene on chromosome
13q12, which consists of 5 exons [6]. A haplotype, "KL-
VS", composed of six single nucleotide polymorphisms
(SNPs), spans exon 2 and its flanking sequence and is
present in approximately 15% of Caucasians [4]. Two of
these SNPs result in amino acid substitutions: F352V
(rs9536314) and C370S (rs9527025). "KL-VS" refers to
the V and S alleles of these SNPs respectively, and since all
six SNPs occur in perfect linkage disequilibrium, a single
variant, F352V, can be used to tag the haplotype [4]. There
is a lower frequency of VV homozygotes in elderly individ-
uals than in newborns (three independent populations: P
= 0.05–0.08; combined analysis (n = 2416): P = 0.0023)
[4]. F352V occurs at a completely conserved amino acid,
and in vitro work shows that KL-VS influences Klotho
expression [4].
The KL-VS variant has been variably associated with early-
onset coronary artery disease (CAD) [7,8] and related phe-
notypes: reduced HDL-cholesterol, increased systolic
blood pressure and stroke [5]. However, these studies are
relatively small and require replication.
The role of the KLOTHO gene in type 2 diabetes is not
known. Given the importance of Klotho in insulin signal-
ling [1-3] and the reduction in insulin production which
co-exists with ageing-related disease in Klotho-deficient
mice [3], we hypothesised that the F352V polymorphism
in KLOTHO would be associated with type 2 diabetes in
the UK Caucasian population. Here we present the results
of a large study, powered to detect odds ratios of ~1.2,
which examines the role of this common functional
KLOTHO variation in type 2 diabetes.
Methods
Subjects
The clinical characteristics of study subjects are shown in
Table 1 and Supplementary Table 1 [see Additional File
1]. All participants gave their informed consent. Case sub-
jects were unrelated UK Caucasians with type 2 diabetes.
Cases were included either if they had type 2 diabetes, as
defined by World Health Organisation criteria [9], or if
they were being treated with medication for diabetes.
Cases were recruited from three sources, as described pre-
viously [10,11]: a collection of young-onset subjects
(YT2D; age at diagnosis 18–45 years; n = 256); probands
from type 2 diabetic sibships from the Diabetes UK War-
ren 2 repository (W2SP; n = 499) [12,13]; and a more
recent collection of cases with type 2 diabetes from the
Diabetes UK Warren 2 repository (W2C; age at diagnosis
35–65 years; not selected for having a family history of
diabetes; n = 1038).
Population control subjects were unrelated UK Cauca-
sians recruited from two sources: parents from a consecu-
tive birth study (Exeter Family Study of Childhood Health
(EFS) [14]; n = 1177) with normal (< 6.0 mmol/l) fasting
glucose and/or normal HbA1c (< 6%, Diabetes Control
and Complications Trial-corrected) [13]; and a nationally
recruited control sample from the European Collection of
Cell Cultures (ECACC) (n = 442). Data on serum concen-
trations of fasting insulin, glucose, triglycerides, HDL- and
LDL-cholesterol were available for EFS subjects.
Subjects for the family-based analysis were recruited as
part of a Warren 2 cohort from across the UK and were
independent of subjects in the case-control analysis. These
Table 1: Clinical characteristics of subjects in study.
Case Subjects Control Subjects Warren 2 Trios and Duos Probands
n 1793 1619 509
Male (%) 58.8 49.4 58.0
Age (years)* 51 (44–58) 32 (29–35) 41 (36–47)
BMI (kg/m2) 30.1 (26.9–34.3) 24.8 (22.1–27.9) 32.3 (28.4–37.2)
Treatment (% D/O/I) 11/62/27 - 18/63/19
Continuous data are given as median (interquartile range). Only successfully genotyped subjects are included.
BMI, body mass index; D/O/I, diet/oral hypoglycaemic agents/insulin. No clinical characteristics were available for the ECACC population control 
subjects, so control age and BMI are for the Exeter Family Study subjects only.
*Age at diagnosis for case subjects; age at study for control subjects.Page 2 of 6
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parents ("trios"; in this study 17 out of the 395 trios were
missing one parent) or an affected proband with one par-
ent and at least one sibling ("duos"; 14 out of the 223 sib-
lings in this study were affected). These families have been
described previously [10,11,15].
Cases and families in which the proband had high GAD
autoantibody levels (> 99th percentile of the normal pop-
ulation) were excluded from the study. Clinical criteria
and/or genetic testing were used to exclude known sub-
types of diabetes such as maturity-onset diabetes of the
young or mitochondrial inherited diabetes and deafness.
Using the same case-control and family-based samples,
associations have recently been shown between the
KCNJ11, K23 allele, [16] the HNF4A P2 promoter haplo-
type [10] and the PPARG P12 allele [17] and type 2 diabe-
tes with odds ratios consistent with other large type 2
diabetes case-control studies and meta-analyses of multi-
ple studies.
Genotyping and quality control
The polymorphism F352V (rs9536314) was genotyped in
all samples. Genotyping was carried out by KBiosciences
(Herts, UK) using its own novel system of competitive
allele-specific PCR (KASPar). Details of assay design are
available from the KBiosciences website [18]. Genotyping
accuracy, as determined from the genotype concordance
between duplicate samples (11.5% of total), was 100% (0
discrepancies/552 informative duplicates). The genotyp-
ing assay success rates were 96.5% for cases, 95.4% for
controls and 96.1% for family samples.
The polymorphism C370S (rs9527025) was genotyped in
307 individuals and confirmed to be in perfect linkage
disequilibrium with F352V (r2 = 1). As a result, we carried
out no further genotyping of this SNP.
Genotypes were in Hardy-Weinberg Equilibrium in cases,
controls and family probands (P > 0.01), and within each
subgroup of cases and controls (P > 0.01).
Statistical analysis
Before combining case and control subgroups, we tested
for homogeneity of allele frequencies using Chi-square
tests. There were no significant differences among the sub-
groups (all P > 0.2). Odds ratios and P values were calcu-
lated using Chi-square tests for our case-control analysis.
Our sample of 1793 cases and 1619 controls gave us 80%
power to detect odds ratios for alleles of 1.20. This power
calculation is for a two-tailed P value < 0.05, assuming a
control V allele frequency of 0.16.
To analyse our family data, we used the FBAT program
[19,20], and we confirmed the result using the TDT/
sibTDT method [21].
To assess the degree of linkage disequilibrium between
the SNPs, we performed a simple correlation analysis
using SPSS v. 11.5 for Windows. We used the ANOVA and
General Linear Model commands in SPSS to analyse the
quantitative trait data available for EFS subjects against
genotype. One-way ANOVA was used to test the null
hypothesis of no difference in the mean of each trait
among all three genotype groups. In addition we used a
recessive model to test the hypothesis that VV individuals
have lower HDL-cholesterol than FF/FV individuals, since
our data for this trait showed a similar (yet non-signifi-
cant) relationship with genotype to that reported previ-
ously [5].
Results
Genotype and allele frequencies for cases and controls are
displayed in Table 2. Genotype and allele frequencies are
shown separately for each subgroup of cases and controls
in Supplementary Table 2 [see Additional File 2]. There
Table 2: Result of case/control and FBAT analyses for SNP F352V.
Genotype or 
Allele
Case-Control Analysis FBAT
Controls (N = 1619) 
Number (Frequency)
Cases (N = 1793) 
Number (Frequency)
Odds Ratio (95% CI) P Observed 
Transmissions 
(V allele)
Expected 
Transmissions 
(V allele)
P
FF 1158 (0.72) 1296 (0.72)
FV 409 (0.25) 447 (0.25) 0.98 (0.84–1.14) 0.74
VV 52 (0.03) 50 (0.03) 0.86 (0.58–1.28) 136 132 0.57
F 2725 (0.84) 3039 (0.85)
V 513 (0.16) 547 (0.15) 0.96 (0.84–1.09) 0.50
P values for the case-control analysis (two-tailed) were calculated using Chi-square tests with a 3 × 2 contingency table (genotypes; 2 d.f.) or a 2 × 
2 contingency table (alleles; 1 d.f.). Odds ratios were calculated relative to genotype FF or allele F. CI, confidence interval.Page 3 of 6
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types and type 2 diabetes.
The results of the FBAT analysis are also presented in Table
2. There was no significant over- or under-transmission of
V352 to the affected offspring. A TDT/sibTDT analysis
confirmed this result (P = 0.62).
Analysis of quantitative trait data in the EFS subjects
showed no evidence for an effect of genotype on fasting
insulin, fasting glucose, Homeostasis Model Assessment
of Insulin Sensitivity (HOMA %S), fasting triglycerides,
HDL-cholesterol or LDL-cholesterol (all P > 0.1). These
results are shown in Table 3, corrected for sex. Females
were pregnant (28 weeks' gestation) when biochemical
data were collected. Analysis of the sexes separately did
not yield any significant associations. However, there was
weak evidence that VV males had lower HDL-cholesterol
levels than FF/FV males (P = 0.07; recessive model). Addi-
tional correction for age and BMI made little difference to
most results, but increased the evidence that VV males had
lower HDL-cholesterol (P = 0.05; recessive model).
Discussion
KLOTHO is a type 2 diabetes candidate gene due to its
importance in insulin signalling, as demonstrated by
murine models, and its potential role in longevity [1-5].
We hypothesised that functional variant V352 (KL-VS)
would be associated with type 2 diabetes. Our case-con-
trol and family-based study results gave no support for
this, despite good power to detect odds ratios of 1.2. Our
study is the first well-powered study of this important var-
iant in type 2 diabetes. Two previous studies have exam-
ined KL-VS in relation to diabetes (approximately 60
affected individuals; approximately 350 unaffected) in
cohorts ascertained for longevity [5] and CAD [7] and
found no association. Whilst we have not captured all
common variation across KL and cannot rule out the
effects of rare variants, we have tested a variant which is
functional and reproducibly associated with longevity.
We can exclude the KL-VS variant from having all but a
minor effect (OR < 1.09 relative to the F allele) on type 2
diabetes susceptibility.
There is suggestive evidence that the KL-VS variant is asso-
ciated with a higher risk of early-onset CAD [7] and with
cardiovascular disease risk factors such as HDL-choles-
terol [5]. Together with the longevity association data,
these findings imply a possible role in susceptibility to
metabolic syndrome. However, the studies are relatively
small. Analysis in our study of quantitative trait data from
1177 healthy individuals showed no significant associa-
tion of KL-VS with HOMA %S, fasting insulin, glucose,
triglycerides, HDL- or LDL-cholesterol. We were unable to
exclude individuals who were taking lipid-lowering med-
ication from this analysis, but since > 92% of these sub-
jects were aged below 40 years, this proportion of subjects
is likely to be negligible. Whilst these subjects are younger
on average than those analysed previously [5,7], we have
analysed a sample that is over twice as large and found no
evidence for association of KL-VS with these phenotypes
in the group as a whole. Thus it is possible that the previ-
ous association with HDL-cholesterol represents a false
positive. We note, however, that our HDL-cholesterol
result shows a similar pattern to previously reported data
[5] and is approaching significance for an association of
the VV genotype with lower HDL-cholesterol in males, but
not in pregnant females. We therefore cannot rule out an
effect and conclude that further large-scale studies will be
required to address this.
Conclusion
This is the first adequately powered study to examine the
association between common functional variation in
KLOTHO and type 2 diabetes. We have examined a poly-
morphism which has been reproducibly associated with
Table 3: Quantitative traits of EFS parents (n = 1177), stratified by F352V genotype.
FF (95% CI) FV (95% CI) VV (95% CI) P
Age (years) 31.9 (31.5–32.2) 32.1 (31.5–32.8) 31.3 (29.5–33.2) 0.68
BMI (kg/m2) 25.0 (24.7–25.2) 24.9 (24.4–25.4) 24.9 (23.7–26.3) 0.96
Fasting insulin (pmol/l) 58.2 (56.1–60.3) 60.0 (56.5–63.8) 59.3 (49.7–70.8) 0.68
Fasting glucose (mmol/l) 4.51 (4.48–4.53) 4.52 (4.48–4.56) 4.52 (4.39–4.66) 0.88
HOMA %S 81.7 (78.7–84.5) 78.0 (73.3–82.8) 79.3 (66.5–94.4) 0.43
Fasting triglycerides (mmol/l) 1.61 (1.56–1.66) 1.67 (1.58–1.75) 1.81 (1.56–2.10) 0.19
LDL-cholesterol (mmol/l) 3.21 (3.14–3.28) 3.22 (3.11–3.34) 3.18 (2.88–3.52) 0.96
HDL-cholesterol (mmol/l) 1.63 (1.61–1.66) 1.64 (1.60–1.69) 1.56 (1.44–1.69) 0.45
HDL-cholesterol (mmol/l)* 1.64 (1.61–1.66) 1.56 (1.44–1.69) 0.23
Data are given as mean (95% confidence interval). For traits other than age, results are corrected for sex. For the serum fasting glucose analysis, 
only values < 6.0 mmol/l were included. All variables apart from age were log-transformed before analysis.
*Recessive model. CI, confidence interval; BMI, body mass index; HOMA %S, Homeostasis Model Assessment of Insulin Sensitivity.Page 4 of 6
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involved in the genetic susceptibility to type 2 diabetes in
our large case-control and family-based study.
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